Research

Research Projects

1. Adjuvant Tamoxifen-Longer Against Shorter (ATLAS).

2. A phase III study of Gemcitabine plus Paclitaxel versus Paclitaxel in patients with unresectable, locally recurrent or metastatic breast cancer. B0E-MC-JHQG.

3. A phase 3 trial of Alimta Vs Docetaxel in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who were previously treated with chemotherapy.

4. A randomized, controlled, open label study to evaluate the efficacy and safety of Herceptin® (trastuzumab) in combination with the oral aromatase inhibitor Arimidex® (anastrozole) compared with Arimidex® alone as first and second line treatment administered to postmenopausal, hormone receptor positive (ER+ve and/or PR+ve) patients with HER2 overexpressing metastatic breast cancer.

5. Multicenter Phase III randomized trial comparing doxorubicin and Cyclophosphamide followed by Docetaxel (AC--t) with Doxorubicin and Cyclophosphamide followed by Docetaxel and Trastuzumab (Erceptin) (AC--TH) and with Docetaxel, Carboplatin and Trastuzumab (TCH) in the Adjuvant treatment of node positive and high risk node negative patients with operable Breast cancer containing the HER2 alteration.

6. A centrally randomized, open multi-center study evaluating the efficacy and safety of combination therapy with Intermax alpha^TM and vinblastine versus vinblastine monothreapy in patients with Advanced Cell Carcinoma

7. A Phase 2 study of Sequential Neoadjuvant Gemcitabine Plus Doxorubicin and Gemcitabine Plus Cisplatin in Large T₂ ( 3cm) and Locally Advanced (T₃ T₄ or N₂) Operable Breast Cancer"

8. A Randomized, double blind, placebo control, phase II study of oral recombinant human lactoferrin (rhLF) in combination with carboplatin and paclitaxel (C/P) chemotherapy in patients with locally advanced and/or metastatic non-small-cell lung cancer (NSCLC)

9. International Multicenter Trial funded by IAEA, Vienna titled “ A randomized study of 5 versus 6 weekly fractions of radiotherapy in the treatment of squamous cell carcinoma of the Head and Neck – Aspects of radiobiology applicable in clinical radiotherapy – increase of the number of fractions per week. IAEA-CRP.E.3.30.18

10. Concurrent chemo-radiotherapy for oropharyngeal and hypopharyngeal cancers.

11. Concurrent chemo-radiotherapy as postoperative adjuvant therapy in operable stomach and hepatobiliary neoplasms.